Gut microbiome alterations in Alzheimer's disease.
Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. · 2017
Read Gut microbiome alterations in Alzheimer's disease. by Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5648830.txt.
Introduction
Vogt and co-authors report a case-control study in Scientific Reports. It profiles gut microbes in Alzheimer's disease patients. Fecal samples came from 25 patients with dementia due to Alzheimer's. Controls were 25 matched people without dementia. Bacterial DNA was read with 16S gene sequencing. The team also checked spinal fluid biomarkers of the disease.
Patient microbiomes showed lower diversity than controls. Their composition was clearly distinct. Firmicutes fell, while Bacteroidetes increased. Bifidobacterium levels dropped as well. Several changed genera tracked spinal fluid biomarker levels. Rodent work had hinted that gut microbes affect amyloid buildup. The authors add Alzheimer's to diseases tied to gut shifts. They propose the gut as a therapy target.
Catalog record
| CREATOR | Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB, Rey FE. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gut microbiome alterations in Alzheimer’s disease By Nicholas M Vogt, Robert L Kerby, Kimberly A Dill-McFarland, Sandra J Harding, Andrew P Merluzzi, Sterling C Johnson, Cynthia M Carlsson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Barbara B Bendlin, Federico E Rey Published in: Scientific Reports DOI: 10.1038/s41598-017-13601-y ABSTRACT Abstract Alzheimer’s disease (AD) is the most common form of dementia. However, the etiopathogenesis of this devastating disease is not fully understood. Recent studies in rodents suggest that alterations in the gut microbiome may contribute to amyloid deposition, yet the microbial communities associated with AD have not been characterized in humans. Towards this end, we characterized the bacterial taxonomic composition of fecal samples from participants with and without a diagnosis of dementia due to AD. Our analyses revealed that the gut microbiome of AD participants has decreased microbial diversity and is compositionally distinct from control age- and sex-matched individuals. We identified phylum- through genus-wide differences in bacterial abundance including decreased Firmicutes, increased Bacteroidetes, and decreased Bifidobacterium in the microbiome of AD participants. Furthermore, we observed correlations between levels of differentially abundant genera and cerebrospinal fluid (CSF) biomarkers of AD. These findings add AD to the growing list of diseases associated with gut microbial alterations, as well as suggest that gut bacterial communities may be a target for therapeutic intervention. INTRODUCTION Despite decades of research, the etiology underlying the development of dementia due to Alzheimer’s disease (AD) remains unknown, and there are currently no preventative or disease-modifying treatments available. In the brain, AD pathology is characterized by extracellular plaques composed of amyloid-β (Aβ) peptide and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein1. However, what causes these hallmark features is unexplained. In recent years, researchers have proposed a potential role for pathogenic microbes, including those derived from the gut, in the development or exacerbation of AD pathology2–5. Humans harbor complex communities of microbes, with the vast majority of the microbial population residing in the distal gut. Gut microbes perform key functions for human health including energy extraction, biosynthesis of vitamins, protection against pathogen overgrowth, and education of the immune system6. Microbial colonization of the gut occurs during birth, is highly dynamic through infancy, and resembles adult structure by about 3 years of age7. Thereafter, the composition of the microbiome within an individual remains generally stable8, albeit with substantial interpersonal variation, particularly in elderly individuals9. Alterations in the composition of this complex ecosystem have been associated with the development of a variety of gastrointestinal and metabolic diseases including inflammatory bowel disease (IBD), obesity, diabetes, and insulin resistance10. More recently, the influence of gut microbiota on central nervous system function – often referred to as the gut-brain axis – has received significant attention, and alterations in the gut microbiome have been associated with neurological conditions including autism spectrum disorder, multiple sclerosis, and Parkinson’s disease11–13. With respect to dementia, a recent study in cognitively impaired elderly participants investigated a limited number of pro- and anti-inflammatory gut bacterial taxa and found altered abundance in individuals with positive amyloid positron emission tomography (PET) imaging14. In addition, recent studies in transgenic mouse models of AD have demonstrated that manipulating gut microbiota can influence cerebral amyloid deposition15,16. However, to date there have been no comprehensive surveys of whole gut microbiota in humans with AD. In this study, we performed bacterial 16S ribosomal RNA (rRNA) gene sequencing of DNA isolated from fecal samples in order to characterize the gut microbial communities in individuals with and without a clinical diagnosis of dementia due to AD. In addition, we examined the relationship between gut microbiota and AD pathology as measured by cerebrospinal fluid (CSF) biomarkers of AD. RESULTS Study Design and Participant Characteristics Participants were recruited from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study (see Methods). Gut microbiome compositional analysis was performed on fecal samples collected from home-dwelling participants with dementia due to AD (n = 25), and age- and sex-matched Control participants (n = 25). Table 1 reports participant characteristics. AD and Control groups did not differ with respect to age, sex, ethnicity, BMI, or diabetes status. There was no difference between groups in total score on a 15-item food questionnaire based on the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet17, which provided a semi-quantitative measure of dietary intake and allowed us to asses dietary differences. As expected, the APOE ε4 genotype was more prevalent in the AD group. The majority of AD participants had very mild or mild dementia, with clinical dementia rating (CDR) scores ranging from 0.5–2. Medication information is reported in Supplementary Table S1. The AD group had a greater number of participants taking selective serotonin reuptake inhibitors (SSRIs), and all but one AD participant was taking an acetylcholinesterase inhibitor (donepezil or rivastigmine) and/or memantine. [Table: Participant characteristics.] Composition of the Gut Microbiome of Control and AD Groups Sequencing of the V4 region of the 16S rRNA gene generated a total of 4.8 million sequence reads (mean ± SD: ~96,000 ± 32,000 reads/participant), which were clustered into operational taxonomic units (OTUs) at 97% similarity and assigned taxonomic classifications down to the lowest phylogenetic level possible (see Methods). The final OTU dataset for AD and Control groups consisted of 972 OTUs classified to 95 genera, 46 families, 24 orders, 17 classes, and 9 phyla. Between groups, there were no differences in percentages of sequences classified to the phylum (Control: 99.6 ± 0.5%, AD: 99.6 ± 0.9%) or genus level (Control: 79.6 ± 7.4%, AD: 83.1 ± 8.1%). Across all 50 participants, the dominant phyla were Firmicutes and Bacteroidetes, which respectively made up 78% (78.1 ± 8.7%) and 15% (14.9 ± 8.4%) of total abundance, with lower contributions from Actinobacteria (2.6%), Verrucomicrobia (2.6%), and Proteobacteria (1.1%) (Supplementary Fig. S1). The predominant bacterial families for all participants were Lachnospiraceae (39.1%), Ruminococcaceae (29.6%), and Bacteroidaceae (9.8%), followed by Verrucomicrobiaceae (2.6%), Clostridiales (1.9%), and Bifidobacteriaceae (1.5%) (Supplementary Fig. S1). AD is Associated with Changes in the Gut Microbiome The composition of the gut microbiome was characterized using traditional ecological measures including richness (the number of unique OTUs present in a participant), alpha diversity (the richness and abundance of OTUs within each participant), and beta diversity (the similarity or difference in composition between participants). For microbiome richness estimates, we used the Abundance-based coverage estimator (ACE) and Chao1; these metrics use non-parametric modeling to calculate a conservative estimate of total OTU richness for each participant. The microbiome of AD participants had reduced richness, with both ACE and Chao1 significantly decreased in the AD group compared to the Control group (t-test; ACE: DF = 48, t = 3.05, p = 0.004; Chao1: DF = 48, t = 2.98, p = 0.004) (Supplementary Fig. S2). For alpha diversity metrics, we used the Inverse Simpson and Shannon Indexes, and Faith’s Phylogenetic Diversity (PD), an alpha diversity metric that also incorporates phylogenetic relationships. While there was a trend towards a decrease in the Inverse Simpson Index between Control and AD groups (Mann-Whitney; U = 227.0, p = 0.097), both the Shannon Index and Faith’s PD were significantly decreased in AD participants compared to Control participants (t-test; Shannon: DF = 48, t = 2.44, p = 0.019, PD: DF = 48, t =